# Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

> **NCT00121602** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 446 (actual)

## Conditions studied

- Anemia
- Kidney Disease

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT00121602
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2005-10
- **Final completion:** 2006-10
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2008-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121602, "Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00121602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*